Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC)

European Journal of Heart Failure - Tập 23 Số 10 - Trang 1610-1632 - 2021
Wouter C. Meijers1, Antoni Bayés‐Genís2, Alexandre Mebazaa3,4,5,6,7, Johann Bauersachs8, John G.F. Cleland9,10, Andrew J.S. Coats11,12, James L. Januzzi13, Alan S. Maisel14, Kenneth McDonald15, Thomas Mueller16, Mark Richards17,18, Petar Seferović19,20, Christian Mueller21, Rudolf A. de Boer1
1Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands
2Heart Institute, Hospital Universitari Germans Trias i Pujol Universitat Autònoma de Barcelona, CIBERCV Barcelona Spain
3Department of Anesthesia and Critical Care Hôpitaux Saint Louis & Lariboisière Paris France
4FHU PROMICE, Paris, France
5Inserm U942-MASCOT
6Inserm U942‐MASCOT; Université de Paris; Department of Anesthesia and Critical Care, Hôpitaux Saint Louis & Lariboisière; FHU PROMICE Paris France
7Université de Paris, Paris, France
8Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany
9Robertson Centre for Biostatistics and Clinical Trials, University of Glasgow
10Robertson Centre for Biostatistics and Clinical Trials, University of Glasgow; National Heart & Lung Institute, Imperial College London London UK
11Monash University, Melbourne, Australia
12University of Warwick, Coventry, UK
13Massachusetts General Hospital, Boston, MA, USA
14University of California, San Diego, CA, USA
15St Vincent’s University Hospital, Dublin, Ireland
16Department of Clinical Pathology, Hospital of Bolzano, Bolzano, Italy
17Cardiovascular Research Institute, National University of Singapore, Singapore
18Christchurch Heart Institute, Christchurch, New Zealand
19Faculty of Medicine, Belgrade University, Belgrade, Serbia
20Serbian Academy of Sciences and Arts, Belgarde, Serbia
21University Hospital Basel, University of Basel, Basel, Switzerland

Tóm tắt

AbstractNew biomarkers are being evaluated for their ability to advance the management of patients with heart failure. Despite a large pool of interesting candidate biomarkers, besides natriuretic peptides virtually none have succeeded in being applied into the clinical setting. In this review, we examine the most promising emerging candidates for clinical assessment and management of patients with heart failure. We discuss high‐sensitivity cardiac troponins (Tn), procalcitonin, novel kidney markers, soluble suppression of tumorigenicity 2 (sST2), galectin‐3, growth differentiation factor‐15 (GDF‐15), cluster of differentiation 146 (CD146), neprilysin, adrenomedullin (ADM), and also discuss proteomics and genetic‐based risk scores. We focused on guidance and assistance with daily clinical care decision‐making. For each biomarker, analytical considerations are discussed, as well as performance regarding diagnosis and prognosis. Furthermore, we discuss potential implementation in clinical algorithms and in ongoing clinical trials.

Từ khóa


Tài liệu tham khảo

10.1002/ejhf.592

10.1016/j.jacc.2013.05.019

10.1161/CIRCULATIONAHA.107.694562

10.1016/j.ahj.2009.06.018

10.1016/j.jacc.2004.06.015

10.1016/j.ijcard.2016.07.117

10.1016/j.cardfail.2016.05.002

10.1002/ejhf.407

10.1002/ejhf.669

10.1002/ejhf.872

10.1002/ejhf.273

10.1002/ejhf.1494

10.1093/eurheartj/ehy462

10.1093/eurheartj/ehs191

10.1016/j.jacc.2019.02.018

10.1161/CIRCULATIONAHA.117.031560

10.1016/j.ahj.2012.03.015

10.1016/j.jacc.2018.04.029

10.1161/01.CIR.103.16.2035

10.1093/eurjhf/hfq210

10.1016/j.jacc.2017.07.718

10.1177/2048872617748553

10.1093/eurheartj/ehs154

10.1373/clinchem.2011.165795

10.1373/clinchem.2017.277186

10.1515/cclm-2016-0933

10.1016/j.cca.2019.06.012

10.1373/clinchem.2012.192716

10.1001/jama.2010.1708

10.1001/jamacardio.2016.0765

10.1161/CIRCULATIONAHA.112.129437

10.1016/j.jchf.2019.12.008

10.1093/eurjhf/hfr047

10.1016/j.cardfail.2018.06.008

10.1002/ejhf.341

10.1093/eurjhf/hfs110

10.1002/ejhf.766

10.1161/CIRCHEARTFAILURE.111.961581

10.1161/CIRCULATIONAHA.106.655076

10.1161/CIRCULATIONAHA.111.044149

10.1161/CIRCHEARTFAILURE.118.005312

10.1007/s12265-015-9618-4

10.1161/CIRCULATIONAHA.114.013748

10.1001/jama.2009.1297

10.1016/S0140-6736(04)15591-8

10.1007/s10157-018-1639-2

Alavi SM, 2012, Can serum procalcitonin measurement help monitor the treatment of acute bacterial meningitis? A prospective study, Caspian J Intern Med, 3, 382

10.1016/j.amjmed.2015.06.037

10.1093/eurjhf/hfr177

10.1016/j.ijcard.2014.06.022

10.1080/1354750X.2017.1420823

10.1002/ejhf.1667

10.1373/clinchem.2019.306787

10.1161/01.CIR.0000116764.53225.A9

10.1093/eurheartj/ehi696

10.1054/jcaf.2002.125289

10.1016/S0002-9149(00)00705-0

10.1016/j.amjmed.2019.05.047

10.1016/j.jchf.2020.03.009

10.1002/ejhf.1627

Makris K, 2016, Acute kidney injury: definition, pathophysiology and clinical phenotypes, Clin Biochem Rev, 37, 85

10.1681/ASN.2007080913

10.1159/000349963

10.1056/NEJMoa0912613

10.1016/S0002-9343(02)01230-5

10.1152/ajprenal.00448.2010

10.1016/S0140-6736(88)91851-X

10.1159/000349962

10.1371/journal.pone.0062691

10.7326/0003-4819-158-11-201306040-00007

10.2217/bmm.13.51

10.1093/ndt/gfs380

10.1016/j.cardfail.2009.07.003

10.1016/j.amjcard.2012.06.035

10.1016/j.cardfail.2011.02.003

10.1016/j.ijcard.2011.07.080

10.1016/j.cardfail.2019.05.009

10.1186/cc12503

10.1016/j.jacc.2016.10.038

10.1038/nature02871

10.1016/j.cell.2012.02.005

10.1093/ndt/gft223

10.1093/toxsci/kfs210

10.1681/ASN.2012050438

10.2215/CJN.00430111

10.1093/ndt/gfl073

10.1080/00365519950185076

10.1038/ki.2008.638

10.1258/0004563021901847

10.1016/j.amjcard.2008.02.098

10.1161/CIRCULATIONAHA.106.644286

10.1016/j.atherosclerosis.2013.04.027

10.1093/eurheartj/ehn598

10.1016/j.jacc.2016.05.092

10.1161/CIRCHEARTFAILURE.112.966960

10.1093/eurheartj/ehl507

10.7150/thno.26055

10.1016/j.ijcard.2014.07.206

10.1161/CIRCHEARTFAILURE.118.005488

10.1097/CCM.0b013e3182978f91

10.7150/thno.22196

10.1016/j.ajpath.2016.05.002

10.1016/j.ejphar.2015.06.025

10.1038/nm.2354

10.1016/j.jacc.2007.04.091

10.1007/s00125-019-4913-2

Mueller T, 2016, Soluble ST2 and galectin‐3: what we know and don't know analytically, EJIFCC, 27, 224

10.1373/clinchem.2016.255174

10.1586/14737159.2014.892421

10.1016/j.cca.2015.10.015

10.1016/j.cca.2015.03.033

10.1016/j.jchf.2016.12.016

10.1016/j.jchf.2016.09.010

10.1007/s10741-019-09858-2

10.2217/bmm.15.121

10.1002/ejhf.331

10.1016/j.ahj.2013.09.013

10.1161/JAHA.118.009555

10.1016/j.amjcard.2013.05.013

10.1016/j.jacc.2017.04.025

10.1002/ejhf.949

10.1186/s12877-018-0807-2

10.1016/j.jacc.2017.09.026

10.1016/j.jacc.2009.07.041

10.1016/j.jacc.2009.08.047

10.1161/CIRCHEARTFAILURE.113.000457

10.1016/j.amjcard.2014.05.062

10.1002/ehf2.12663

10.3109/07853890.2010.538080

10.1016/j.ahj.2014.02.011

10.1016/j.jacc.2012.04.053

10.1136/heartjnl-2015-308975

10.1016/j.amjcard.2016.09.019

10.1016/j.cardfail.2015.07.017

10.1161/CIRCHEARTFAILURE.112.000129

10.1016/j.cardfail.2015.10.022

10.1016/j.ahj.2014.12.012

10.1016/j.cardfail.2013.11.011

10.1002/ejhf.1716

10.1038/s41591-021-01457-9

10.1093/eurheartj/ehaa758

10.1002/ejhf.749

10.1016/j.jchf.2017.07.013

10.1002/ejhf.1301

10.1016/j.cardfail.2019.07.003

10.1093/eurjhf/hfs120

10.1016/j.jchf.2014.06.013

10.1164/rccm.200712-1786OC

10.1164/rccm.200802-235OC

10.1002/ejhf.1575

10.1373/clinchem.2016.260471

10.1002/ejhf.1050

10.1093/ndt/gfy113

10.1016/j.jacc.2016.04.060

10.1056/NEJMoa1409077

10.1056/NEJMoa1812851

10.1001/jama.2019.12821

10.1001/jama.2019.12843

10.1056/NEJMoa1908655

10.1016/j.jacc.2018.11.042

10.1016/j.jacc.2020.05.072

10.1038/srep33495

10.1093/cvr/cvw166

10.1186/s13613-017-0238-9

10.1371/journal.pone.0201491

10.3390/healthcare6030110

10.1186/cc3885

10.1186/cc13830

10.1001/archsurg.133.12.1298

10.1186/2197-425X-1-3

10.1186/2197-425X-1-2

10.1161/JAHA.117.005712

10.1007/s00392-020-01597-x

10.1373/jalm.2017.023655

10.1016/j.ijcard.2015.07.039

10.1016/j.ejim.2016.05.008

10.1186/s12872-020-01435-y

10.1002/ejhf.1437

10.1093/eurheartj/ehx679

10.1016/j.ajem.2015.10.033

10.1016/j.ijcha.2019.02.011

10.1002/ejhf.1693

10.1016/j.ahj.2020.09.012

10.1056/NEJMra1401038

10.1161/CIRCHEARTFAILURE.117.004519

10.1016/j.ijcard.2017.04.110

10.1002/ejhf.1305

10.1136/heart.84.4.455

10.1210/jc.2011-1978

10.1161/CIRCHEARTFAILURE.118.005266

10.1038/nrcardio.2016.174

10.1007/s10557-018-6808-8

10.1016/j.cardfail.2015.10.005

10.1093/ajcn/nqz192

10.1093/eurheartj/ehaa270

10.1016/j.cbpa.2008.07.024

10.1038/nbt0208-164

10.1023/A:1025433721505

10.1002/pmic.200500856

10.1002/pmic.201100568

10.1002/ehf2.12136

10.1002/pmic.201600097

10.1038/s41467-019-13690-5

10.1371/journal.pone.0157167

10.1002/ejhf.544

10.1007/s12265-015-9661-1

10.1038/nature12345

10.1161/CIRCHEARTFAILURE.119.006794

10.1038/s41588-018-0183-z

10.1038/s41598-018-27382-5

10.1001/jamacardio.2018.1717

10.1001/jama.2017.10565

10.1016/j.jchf.2017.11.003